Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Atlas Venture Life Science Advisors, LLC (CIK 1917529) reported $881.3M across 7 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: KYMR ($326.5M, 37.05%), DYN ($151.0M, 17.14%), SION ($131.8M, 14.95%), KLRA ($113.9M, 12.93%), IRON ($110.7M, 12.56%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | KYMR | Kymera Therapeutics, Inc. | $326.5M | 37.05% | 2.8M | Trimmed |
| 2 | DYN | Dyne Therapeutics, Inc. | $151.0M | 17.14% | 6.8M | Trimmed |
| 3 | SION | Sionna Therapeutics, Inc. | $131.8M | 14.95% | 3.0M | Hold |
| 4 | KLRA | Kailera Therapeutics, Inc. | $113.9M | 12.93% | 5.2M | New |
| 5 | IRON | Disc Medicine, Inc. | $110.7M | 12.56% | 1.5M | Hold |
| 6 | QTTB | Q32 Bio, Inc. | $34.6M | 3.93% | 2.7M | Added |
| 7 | KRRO | Korro Bio, Inc. | $12.7M | 1.44% | 962,884 | Trimmed |
Source: SEC Form 13F filings · as of 2026-06-30